These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2452923)

  • 21. Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499].
    Lynch JJ; Wallace AA; Stupienski RF; Baskin EP; Beare CM; Appleby SD; Salata JJ; Jurkiewicz NK; Sanguinetti MC; Stein RB
    J Pharmacol Exp Ther; 1994 May; 269(2):541-54. PubMed ID: 7802864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recainam, a potent new antiarrhythmic agent: effects on complex ventricular arrhythmias.
    Anastasiou-Nana MI; Anderson JL; Hampton EM; Nanas JN; Heath BM
    J Am Coll Cardiol; 1986 Aug; 8(2):427-35. PubMed ID: 3734265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias.
    Davies RF; Lineberry MD; Funck-Brentano C; Echt DS; Lee JT; Capuzzi DM; Roden DM; Woosley RL
    Clin Pharmacol Ther; 1989 Sep; 46(3):324-34. PubMed ID: 2673622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiarrhythmic profile of a new class 1 drug, AHR 10718, on canine atrial and ventricular arrhythmia models.
    Mitsuhashi H; Hashimoto K
    Jpn J Pharmacol; 1988 Apr; 46(4):349-58. PubMed ID: 3404765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent: effects on cardiac conduction.
    Hidaka T; Hamasaki S; Aisaka K; Ishihara T; Morita M; Toyama J; Yamada K
    Arzneimittelforschung; 1985; 35(9):1381-6. PubMed ID: 4084339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent.
    Gwilt M; Dalrymple HW; Burges RA; Blackburn KJ; Dickinson RP; Cross PE; Higgins AJ
    J Cardiovasc Pharmacol; 1991 Mar; 17(3):376-85. PubMed ID: 1711597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
    Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
    Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac electrophysiologic and antiarrhythmic actions of tedisamil.
    Wallace AA; Stupienski RF; Baskin EP; Appleby SD; Kothstein T; Gehret JR; King SW; Remy DC; Lynch JJ
    J Pharmacol Exp Ther; 1995 Apr; 273(1):168-75. PubMed ID: 7714763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac electrophysiological effects of bupivacaine in the anesthetized dog: relation with plasma concentration.
    Eledjam JJ; de la Coussaye JE; Brugada J; Masse C; Desh G; d'Athis F; Sassine A
    Arch Int Pharmacodyn Ther; 1988; 295():147-56. PubMed ID: 3245730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrophysiologic evaluation of encainide with use of monophasic action potential recording.
    Samuelsson RG; Harrison DC
    Am J Cardiol; 1981 Nov; 48(5):871-6. PubMed ID: 6795911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs.
    Wallace AA; Stupienski RF; Brookes LM; Selnick HG; Claremon DA; Lynch JJ
    J Cardiovasc Pharmacol; 1991 Nov; 18(5):687-95. PubMed ID: 1723765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiarrhythmic, electrophysiologic and hemodynamic effects of ACC-9358.
    Brown BS; Calzadilla SV; Diemer MJ; Hartman JC; Reynolds RD
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1225-34. PubMed ID: 3694532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency- and voltage-dependent effects of recainam on the upstroke velocity of action potential in rabbit ventricular muscle.
    Kamiya K; Takikawa R; Singh BN
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):630-7. PubMed ID: 2471002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of recainam, a new antiarrhythmic drug, for control of ventricular arrhythmias.
    Anderson JL; Anastasiou-Nana MI; Heath BM; Menlove RL; Nanas JN; Friedman J
    Am J Cardiol; 1987 Aug; 60(4):281-7. PubMed ID: 2441587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiarrhythmic and electrophysiologic effects of MDL 11,939, a novel class III antiarrhythmic agent in anesthetized dogs.
    Koerner JE; Dage RC
    J Cardiovasc Pharmacol; 1990 Sep; 16(3):383-93. PubMed ID: 1700208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasoactive intestinal polypeptide facilitates atrioventricular nodal conduction and shortens atrial and ventricular refractory periods in conscious and anesthetized dogs.
    Rigel DF; Lathrop DA
    Circ Res; 1990 Dec; 67(6):1323-33. PubMed ID: 2245498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative cardiac electrophysiologic study of PK 10139, a new antiarrhythmic agent, and quinidine in anesthetized dogs: plasma concentration-response relationships.
    Heckle J; Jaillon P; Jozefczak C; Cheymol G
    J Cardiovasc Pharmacol; 1985; 7(1):18-25. PubMed ID: 2580140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrophysiologic and hemodynamic effects of H 234/09 (almokalant), quinidine, and (+)-sotalol in the anesthetized dog.
    Duker G; Almgren O; Carlsson L
    J Cardiovasc Pharmacol; 1992 Sep; 20(3):458-65. PubMed ID: 1279293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac electrophysiologic and antiarrhythmic actions of 3,4-dihydro-1'-[2-(benzofurazan-5-yl) ethyl]-6-methanesulfonamidospiro [(2H)-1-benzopyran-2,4'-piperidin]-4-one HCl (L-691,121), a novel class III agent.
    Lynch JJ; Wallace AA; Van der Gaag LH; Baskin EP; Bear CM; Gehret JR; Kothstein T; Stupienski RF; Appleby SD; Sanguinetti MC
    J Pharmacol Exp Ther; 1993 May; 265(2):720-30. PubMed ID: 8496818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.